Sign up
Pharma Capital

ResApp Health director provides share support through on-market buying

ResApp has adult and paediatric clinical studies underway in the U.S. and Australian.
ResApp shares are up today

ResApp Health Ltd's (ASX:RAP) executive director, Brian Leedman, has provided support for the company's valuation through the purchase of 876,000 shares on-market this week for a consideration of $64,500.

Leedman's stake in the company is now 21.5 million shares, along with 18.75 million performance shares and several lines of director incentive options.

A separate company holding has 4.5 million shares, along with the same number of performance shares.

ResApp has a business strategy of developing smartphone applications for the diagnosis and management of respiratory disease.

Shares in the company have climbed 9.3% today to $0.082. A year earlier shares were trading in the mid $0.40 range.

Register here to be notified of future RAP Company articles
View full RAP profile

ResApp Health Ltd Timeline

View All

Related Articles

generic pill and bottle shot to denote Alliance's products
The company has made the transition from a business capitalised at £90mln to company now worth around a quarter of a billion pounds - but has the market at large picked up on (and priced in) the transformation?
scientist in a lab
“I strongly believe that ValiRx and its assets offer investors or joint venture partners an increasingly attractive and investable proposition as we strengthen our position among frontrunners in the fields of personalised and precision medicine"

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.